solid results/busi clarif indic thesi track
report strong quarter top bottom line importantli
compani spent meaning time earn call discuss futur healthcar
combin aetna succeed evolv competit landscap
think comment combin opportun expand store
today telehealth initi exampl begin strateg
evolut relat aetna deal furthermor disclos current expect
rebat ep act somewhat de-risk direct
potenti risk drug price chang continu believ steadi
cash flow-gener behemoth potenti meaning pivot busi
broader healthcar deliveri model post aetna deal stock trade
low end histor trade rang see risk/reward incred
favor skew reiter buy rate increas price object po
po equat roughli pf ep
ep slightli follow solid oper result
follow earn increas ep also
increas ep driven strong perform
 well increment cost save opportun busi post-aetna
acquisit back increas estim increas po
new po repres price-to-earnings multipl
upcom event catalyst
news on-going deal review process could serv catalyst
share compani expect late earli close dc headlin could
also impact share includ comment manufactur rebat chang medicar
part b/part item also look activ engag
invest commun pitch merit transact addit
amazon purchas pharmaci asset close transact well
increment commentari amazon pharmaci plan could impact share
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
one largest healthcar compani
unit state provid retail mail
specialti pharmaci dispens servic
pharmaci benefit upon complet
acquisit aetna would becom one
vertic integr publicli trade
healthcar compani base
buy rate driven transform
vertic integr aetna assum deal
close stabl free cash flow appeal
valuat think compani deal aetna
provid ampl short-term long-term synergi
opportun provid clear way extract
valu retail franchis stabl
free cash flow three busi
allow compani gener outsiz
return equiti next year
sever state alreadi approv transact
state wait doj approv vote
impact divestitur medicar part would
minuteclin offer video visit telehealth app
leverag teladoc platform
goodwil impair charg omnicar
industry-wid financi challeng creat unintend
impair driven higher amount bad debt weaker
gross margin improv gross profit dollar increas
expect gener gross benefit streamlin
initi year
incom tax rate significantli improv y/i due tax reform
revenu growth exceed high end guidanc
driven higher mix specialti drove higher
continu price pressur impact gener
pbm adjust claim grew
gross margin gener flat y/i
time client commit suppos impact
chang impact busi later year
outlook
benchmark result show
silverscript qualifi region
benchmark deminimi region
assum propos transact close end
guidanc purpos includ aet oper
full year narrow guidanc
invest tax save spent
vast major retail segment
retail segment made better progress
pharmaci initi strong flu season
challeng impact second half
time shift pbm client contractu commit
move
expect adjust ep
tax reform major contributor increas
effect compet futur compani need integr
lower cost model care deliveri crucial particularli
return rebat client number chang
valu pass back client
commerci market versu medicar bypass idea rebat still abl
reason profit
mani pilot around value-bas care mani compani
still test one offer overwhelm share
retent rate ahead recent year good indic custom
look transact posit light
rfp activ lower year
activ marketplac client want
see shake
propos rule step edit part part
see propos rule real opportun bigger
opportun aet come togeth
chang client commentari relat blueprint
client reli go detail blueprint
long close expect offer plan design could lower cost
front end
realist new plan design would make way
busi
prefer network opportun see next year
rx growth come three bucket partner payer
organ take share market
omnicar quickli compani address challeng
compani new manag team place
growth pbm driven specialti
obvious movement brand gener big
driver growth busi model
beyond rebat could speak re-contract current client
would anticip market chang dramat fashion
compani would opportun
believ contract provid flexibl
client choos rebat pass model profit
retent rate higher year past without
client underwritten target margin rate
long chang model dampen rfp activ
requir closur question activ marketplac
key driver peopl take long-term view
term understand futur marketplac line
price object base ep estim multipl
five-year averag absolut basi toward lower end
histor rang also repres bigger discount vs
last five year discount reflect margin pressur across core pharmaci
servic retail pharmaci segment uncertainti around drug price
downsid risk po risk amazon anoth disrupt forc enter
suppli chain failur close aetna transact close gener expect
synergi aetna transact grow competit risk pharmaci benefit
market slow prescription/insur trend upsid risk po
potenti prescript volum pickup faster stronger expect synergi
aetna improv front-end perform
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
